[HTML][HTML] Pregnancy-associated changes in pharmacokinetics: a systematic review

G Pariente, T Leibson, A Carls, T Adams-Webber… - PLoS …, 2016 - journals.plos.org
Background Women are commonly prescribed a variety of medications during pregnancy.
As most organ systems are affected by the substantial anatomical and physiological …

HIV-1 integrase inhibitors: a comparative review of efficacy and safety

KK Scarsi, JP Havens, AT Podany, SN Avedissian… - Drugs, 2020 - Springer
The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

[HTML][HTML] Integrase strand transfer inhibitors are effective anti-HIV drugs

SJ Smith, XZ Zhao, DO Passos, D Lyumkis, TR Burke Jr… - Viruses, 2021 - mdpi.com
Integrase strand transfer inhibitors (INSTIs) are currently recommended for the first line
treatment of human immunodeficiency virus type one (HIV-1) infection. The first-generation …

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

N Mulligan, BM Best, J Wang, EV Capparelli, A Stek… - Aids, 2018 - journals.lww.com
Objective: To evaluate dolutegravir pharmacokinetics during pregnancy compared with
postpartum and in infant washout samples after delivery. Design: Ongoing, nonrandomized …

Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors

AT Podany, KK Scarsi, CV Fletcher - Clinical pharmacokinetics, 2017 - Springer
Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the
latest class of antiretrovirals (ARVs) that have become available to treat human …

HIV viraemia and mother‐to‐child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa

L Myer, TK Phillips, JA McIntyre, NY Hsiao… - HIV …, 2017 - Wiley Online Library
Objectives Maternal HIV viral load (VL) drives mother‐to‐child HIV transmission (MTCT) risk
but there are few data from sub‐Saharan Africa, where most MTCT occurs. We investigated …

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

C Fernandez, CL van Halsema - HIV/AIDS-Research and Palliative …, 2019 - Taylor & Francis
Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …

[HTML][HTML] HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity

L Cerveny, P Murthi, F Staud - … et Biophysica Acta (BBA)-Molecular Basis of …, 2021 - Elsevier
An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is
associated with adverse pregnancy outcomes and all HIV-positive pregnant women …

Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review

AT Podany, KK Scarsi, MM Pham, CV Fletcher - Clinical pharmacokinetics, 2020 - Springer
Abstract Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of
the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) …

[HTML][HTML] Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps

R van der Galiën, R Ter Heine, R Greupink… - Clinical …, 2019 - Springer
Prevention of mother-to-child transmission of HIV and optimal maternal treatment are the
most important goals of antiretroviral therapy in pregnant women with HIV. These goals may …